Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (6786)	2/18/2000 7:58:00 PM
From: BDR	Read Replies (1) \| Respond to of 10293

<<The GUMM fraud continues its collapse...>> And they were just beginning to wup QGLY's butt: DOLYESTOWN, Pa., Feb. 18 /PRNewswire/ -- The Quigley Corporation (Nasdaq: QGLY) today announced results for the fourth quarter and year ended December 31, 1999. The Company reported three-month and year-end revenues of $12.5 million and $24.8 million, compared to revenues of $17.0 million and $36.4 million for the comparable periods ended December 31, 1998. Net losses for 1999 were $1.3 million, or $0.12 per share, for the fourth quarter and $4.2 million, or $0.37 per share for the year. In 1998, net income for the three months and year ended December 31 were $2.5 million and $6.8 million, or diluted earnings per share of $0.18 and $0.46. . . . Lower revenues for the fourth quarter as well as the year of 1999, compared to 1998 revenues, can be attributed to the following market conditions: -- New herbal and other so called "natural" cold treatments reported by the media as the latest "cure for the common cold," as well as, inaccurate reports on the efficacious claims of COLD-EEZE(R). The Company is permitted currently, as in the past, to make advertising claims that COLD-EEZE has been proven, in two double-blind placebo controlled studies at prestigious institutions, to reduce the duration and severity of the common cold symptoms by 42%; -- Consumer confusion caused by other zinc products that are not clinically proven to work, along with some of these products being discontinued and sold at severely discounted prices; -- Change in the purchase patterns of wholesalers, retailers and the consumers to buy COLD-EEZE only when needed as opposed to previously having up to an eight week supply; and -- Consolidation of many retailers leading to reduced pipeline inventories and subsequent reorders of COLD-EEZE, as well as their merchandising efforts, which were confusing to the consumer.

To: Bill Wexler who wrote (6786)	2/19/2000 10:45:00 AM
From: DanZ	Read Replies (1) \| Respond to of 10293

<The GUMM fraud continues its collapse while VPHM trends higher.> You've got to be kidding! GUMM was down a measly 7/8 of a point on Friday on a day when the DJIA was down 295, the Nasdaq was down 137, and the S&P 500 was down 42. You call this a "collapse" LMFAO! There's very little similarity between VPHM and GUMM and it doesn't make much sense to compare them. Here's how some of your favorite stocks performed last week: ONE: -2 1/2 (-9.4%) COST: -6 3/4 (-13.1%) good thing that it finished 3 points off the low! GUMM: +1/8 (+0.6%)! Shoud I infer from these facts that ONE and COST are perpetrating frauds?? Their stocks were down about 10% last week and GUMM was actually up! I think that it's more likely that Wexler is perpetrating the stock fraud. You tout your short position in stocks like VLNC, REFR, and GUMM much more than anyone who is long. <Not surprising since VPHM's product - while it may not gain approval - is at least based on real science as opposed to quackery/Homeopathy.> Again, Mr. Know-It-All-NOT: The interaction of zinc ions with the rhinovirus and ICAM-1 is SCIENCE. The FDA permits Zicam to be LABLED as homeopathic because its active ingredient is contained in the homeopathic pharmacopeia of the United States. If you don't understand the difference between SCIENCE and LABELING issues, it's no wonder that you stupidly shorted GUMM from 11 to 20 something and are well under water on your position despite the pull back from 35. <The last earnings report was horrible and I'm certain that the next will be absolutely dismal.> The last earnings report was "horrible" only in your warped mind. How was it "horrible"? Are you as certain that the next report will be "dismal" as you were that sales of Zicam would be "neglible"? You have NEVER been right about GUMM on any substantive issue. You are simply full of hot air and have been proven wrong time and time again and will be proven wrong in the future. For the record, what would you consider "dismal" earnings for the first quarter? If you aren't willing to answer this, then you are just blowing hot air. Tell us what would be dismal so we will have something to compare the actual results to. Here are some facts about Gum Tech's financials. YTY quarterly sales comparisons higher eight consecutive quarters. 1997 vs. 1998 Q1: +52.5% Q2: +107.7% Q3: +0.1% Q4: +41.1% 1998 vs. 1999 Q1: +121.6% Q2: +58.2% Q3: +76.4% Q4: +432.9% In the quarter that you characterize as "horrible", the company increased their sales 432.9% from the same period last year and 292% sequentially from the third quarter of 1999. They made 13 cents per share, the first profit in several years. How in the hell is this "horrible"? Here are some more facts: Gum Tech will be debt free as of the March balance sheet. This means ZERO debt. Citadel is completely paid off and so is all their other debt. Of course, this excludes accounts payable that will be on the books as of March 00. In addition, the company is sitting on a wad of cash due to the exercise of options over the last few months and earnings in Q4 99 and Q1 00. My, how quickly Gum Tech's balance sheet obsoleted the arguments about the company's financial condition from the critics here. This is what can happen when a small company has success with products in markets that are huge compared to their size. It's only going to get better for Gum Tech shareholders. You are fighting a losing battle with this stock. According to my estimate, sales will be up about 500% YTY in the March 00 quarter, and up about 70% sequentially from the fourth quarter 99. Only a fool would short a company that has nine consecutive quarters of rapidly rising sales, more new products on the way that have already been announced that will sustain the growth, and obvious profits that justify a much higher valuation.